Fig. 4

The effects of telmisartan on the migration of human LN229 and LNZ308 glioblastoma cells measured by wound healing assays and transwell invasion assays. A–C left, LN229, U87MG, and LNZ308 glioma cells were pretreated with mitomycin C overnight; the monolayers formed in 6-well plates were scratched, and the remaining cells were incubated with or without telmisartan for 16 h and 24 h. The groups treated with telmisartan for 48 h at the indicated dosage significantly had a significantly higher the wound area than the control groups in LN229, U87MG, and LNZ308 cells. The wound area was analyzed with ImageJ software and expressed relative to hour 0 (n ≥ 3; ***p < 0.001). A–C right, Representative photomicrographs of the underside of transwell filters demonstrating that compared to untreated cells, fewer glioma cells treated with telmisartan crossed the membrane from the upper chamber. These data demonstrated telmisartan suppressed the migration and invasion of human LN229, U87MG, and LNZ308 glioma cells